These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3234253)

  • 1. Rapid methylprednisolone clearance in a patient with cystic fibrosis.
    Green CG; Kraus CK; Lemanske RF; Farrell PM; Jusko WJ
    Drug Intell Clin Pharm; 1988 Nov; 22(11):876-8. PubMed ID: 3234253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloxacillin absorption and disposition in cystic fibrosis.
    Spino M; Chai RP; Isles AF; Thiessen JJ; Tesoro A; Gold R; MacLeod SM
    J Pediatr; 1984 Nov; 105(5):829-35. PubMed ID: 6502318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered prednisolone pharmacokinetics in patients with cystic fibrosis.
    Dove AM; Szefler SJ; Hill MR; Jusko WJ; Larsen GL; Accurso FJ
    J Pediatr; 1992 May; 120(5):789-94. PubMed ID: 1578318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients.
    Tornatore KM; Reed K; Walshe JJ; Venuto RC
    Pharmacotherapy; 1994; 14(1):111-8. PubMed ID: 8159595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theophylline disposition in cystic fibrosis.
    Isles A; Spino M; Tabachnik E; Levison H; Thiessen J; MacLeod S
    Am Rev Respir Dis; 1983 Apr; 127(4):417-21. PubMed ID: 6838048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Pharmacol Toxicol; 1999 Jul; 85(1):29-32. PubMed ID: 10426160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of high-dose methylprednisolone in children.
    Ito S; Kusunoki Y; Oka T; Ito Y; Okuno A; Yoshioka H
    Dev Pharmacol Ther; 1992; 19(2-3):99-105. PubMed ID: 1340442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
    Cirillo I; Vaccaro N; Redman R; Black PL; Kearns GL
    J Clin Pharmacol; 2012 Nov; 52(11):1645-53. PubMed ID: 22174436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019.
    De Sutter PJ; Gasthuys E; Van Braeckel E; Schelstraete P; Van Biervliet S; Van Bocxlaer J; Vermeulen A
    Clin Pharmacokinet; 2020 Dec; 59(12):1551-1573. PubMed ID: 32808233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics.
    Slayter KL; Ludwig EA; Lew KH; Middleton E; Ferry JJ; Jusko WJ
    Clin Pharmacol Ther; 1996 Mar; 59(3):312-21. PubMed ID: 8653994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered PABA pharmacokinetics in cystic fibrosis. Implications for bentiromide test.
    Koren G; Weizman Z; Forstner G; MacLeod SM; Durie PR
    Dig Dis Sci; 1985 Oct; 30(10):928-32. PubMed ID: 3875462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probenecid pharmacokinetics in cystic fibrosis.
    Weber A; de Groot R; Ramsey B; Williams-Warren J; Smith A
    Dev Pharmacol Ther; 1991; 16(1):7-12. PubMed ID: 1879255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.
    Kearns GL; Hilman BC; Wilson JT
    J Pediatr; 1982 Feb; 100(2):312-8. PubMed ID: 7035640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease.
    Ludwig EA; Kong AN; Camara DS; Jusko WJ
    J Clin Pharmacol; 1993 Sep; 33(9):805-10. PubMed ID: 8227476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients.
    Keller F; Hemmen T; Schöneshöfer M; Schwarz A; Offermann G
    Transplantation; 1995 Aug; 60(4):330-3. PubMed ID: 7652760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug disposition in cystic fibrosis.
    Rey E; Tréluyer JM; Pons G
    Clin Pharmacokinet; 1998 Oct; 35(4):313-29. PubMed ID: 9812180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
    Touw DJ
    Pharm World Sci; 1998 Aug; 20(4):149-60. PubMed ID: 9762727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.
    Möllmann H; Rohdewald P; Barth J; Möllmann C; Verho M; Derendorf H
    Pharm Res; 1988 Aug; 5(8):509-13. PubMed ID: 3072558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of methicillin in patients with cystic fibrosis.
    Yaffe SJ; Gerbracht LM; Mosovich LL; Mattar ME; Danish M; Jusko WJ
    J Infect Dis; 1977 May; 135(5):828-31. PubMed ID: 404369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.